Company intelligence
AlzeCure Pharma
Developing groundbreaking treatments for Alzheimer’s disease, pain conditions and other severe CNS disorders. Learn more
About AlzeCure Pharma
AlzeCure Pharma is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease. The company also has a project in the field of pain in the early preclinical phase, TrkA-NAM. FNCA Sweden AB is the company’s certified adviser: contact +46(0)8-528 00 399, info@fnca.se. For further information, please visit our website at www.alzecurepharma.se.
Verified activity
Signals from AlzeCure Pharma
13 published signals
Presence & Recognition
AlzeCure Pharma's CEO Martin Jönsson is presenting at the Stockholm Aktiespararnas Aktiedagen on September 15, 2026, at 16:25 CET.
Reported by AlzeCure Pharma
Presence & Recognition
AlzeCure Pharma participated in the opening panel session for the NLS Days 2026 alongside CEO Martin Jönsson, BioArctic CEO Gunilla Osswald, SwedenBIO CEO Jessica Martinsson, Actithera CEO Andreas Goutopoulos, and SwedenBio's International Director Marjo Puumalainen.
Reported by AlzeCure Pharma
Presence & Recognition
AlzeCure Pharma participated in the opening panel session for the NLS Days 2026 alongside CEO Martin Jönsson, BioArctic CEO Gunilla Osswald, SwedenBIO CEO Jessica Martinsson, Actithera CEO Andreas Goutopoulos, and SwedenBio's International Director Marjo Puumalainen.
Reported by AlzeCure Pharma
Presence & Recognition
AlzeCure Pharma SwedenBIO participated in a panel discussion hosted by Hannah Kite and the Potter Clarkson Team.
Reported by AlzeCure Pharma
Presence & Recognition
AlzeCure Pharma announced an interview with Martin Jönsson from Intervju regarding the company's progress in the second quarter of 2026.
Reported by AlzeCure Pharma
Partnerships
AlzeCure Pharma entered into an out-licensing agreement with Eli Lilly for Alzstatin® (ACD680), a novel disease-modifying and preventive approach for Alzheimer's disease.
Reported by AlzeCure Pharma
Partnerships
AlzeCure Pharma entered into a recent out-licensing agreement with QuantumCell for NeuroRestore® (ACD856) a drug candidate in clinical development designed to enhance cognitive function and support brain signaling pathways.
Reported by AlzeCure Pharma
Presence & Recognition
AlzeCure Pharma was interviewed by Redeye on August 26, 2026, covering Martin Jönsson and Johan Sandin regarding the historical quarter affected by two licensing agreements with Eli Lilly and QuantumCell.
Reported by AlzeCure Pharma
Presence & Recognition
AlzeCure Pharma employee Cecilia Hallström and Jonas Söderström were invited to BioStock to talk about the company's latest developments and plans.
Reported by AlzeCure Pharma
Partnerships
AlzeCure Pharma collaborated with Eli Lilly and QuantumCell on Alzheimer’s projects.
Reported by AlzeCure Pharma
Presence & Recognition
AlzeCure Pharma is presenting at the Pareto Securities’ Annual Healthcare Conference on Wednesday September 2nd at 17:05 CET.
Reported by AlzeCure Pharma
Products & Services
AlzeCure Pharma announced a recent out-licensing agreement and ongoing collaboration with QuantumCell for NeuroRestore® (ACD856), a drug candidate in clinical development designed to enhance cognitive function and support brain signaling pathways.
Reported by AlzeCure Pharma
Products & Services
AlzeCure Pharma announced a partnership with Eli Lilly for the development of Alzstatin® (ACD680), a novel disease-modifying and preventive approach for Alzheimer's disease.
Reported by AlzeCure Pharma